4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse
Model of Osteogenesis Imperfecta

J 2022

4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta

DURAN, I., J. ZIEBA, F. CSUKASI, J. H. MARTIN, D. WACHTELL et. al.

Basic information

Original name

4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta

Authors

DURAN, I., J. ZIEBA, F. CSUKASI, J. H. MARTIN, D. WACHTELL, M. BARAD, B. DAWSON, Bohumil FAFÍLEK (203 Czech Republic, belonging to the institution), C. M. JACOBSEN, C. G. AMBROSE, D. H. COHN, Pavel KREJČÍ (203 Czech Republic, belonging to the institution), B. H. LEE and D. KRAKOW (guarantor)

Edition

Journal of bone and mineral research, Hoboken, Wiley, 2022, 0884-0431

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30202 Endocrinology and metabolism

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.200

RIV identification code

RIV/00216224:14110/22:00129049

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/jbmr.4501

UT WoS

000748116400001

Keywords in English

osteogenesis imperfecta; Aga2; bone; 4-PBA; ER stress; Chop(-/ -); Bip(+/-)

Abstract

V originále

Osteogenesis imperfecta (OI) is a genetically heterogenous disorder most often due to heterozygosity for mutations in the type I procollagen genes, COL1A1 or COL1A2. The disorder is characterized by bone fragility leading to increased fracture incidence and long-bone deformities. Although multiple mechanisms underlie OI, endoplasmic reticulum (ER) stress as a cellular response to defective collagen trafficking is emerging as a contributor to OI pathogenesis. Herein, we used 4-phenylbutiric acid (4-PBA), an established chemical chaperone, to determine if treatment of Aga2(+/-) mice, a model for moderately severe OI due to a Col1a1 structural mutation, could attenuate the phenotype. In vitro, Aga2(+/-) osteoblasts show increased protein kinase RNA-like endoplasmic reticulum kinase (PERK) activation protein levels, which improved upon treatment with 4-PBA. The in vivo data demonstrate that a postweaning 5-week 4-PBA treatment increased total body length and weight, decreased fracture incidence, increased femoral bone volume fraction (BV/TV), and increased cortical thickness. These findings were associated with in vivo evidence of decreased bone-derived protein levels of the ER stress markers binding immunoglobulin protein (BiP), CCAAT/-enhancer-binding protein homologous protein (CHOP), and activating transcription factor 4 (ATF4) as well as increased levels of the autophagosome marker light chain 3A/B (LC3A/B). Genetic ablation of CHOP in Aga2(+/-) mice resulted in increased severity of the Aga2(+/-) phenotype, suggesting that the reduction in CHOP observed in vitro after treatment is a consequence rather than a cause of reduced ER stress. These findings suggest the potential use of chemical chaperones as an adjunct treatment for forms of OI associated with ER stress. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Links

GA17-09525S, research and development project

Name: Neobvyklé signální dráhy lidských receptorových tyrozinových kináz

Investor: Czech Science Foundation

GA19-20123S, research and development project

Name: Regulace časného vývoje savčí končetiny pomocí nestabilních morfogenů z rodiny FGF (Acronym: Regulace časného vývoje savčí končetiny)

Investor: Czech Science Foundation

Citovat

DURAN, I., J. ZIEBA, F. CSUKASI, J. H. MARTIN, D. WACHTELL, M. BARAD, B. DAWSON, Bohumil FAFÍLEK, C. M. JACOBSEN, C. G. AMBROSE, D. H. COHN, Pavel KREJČÍ, B. H. LEE and D. KRAKOW. 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta. Journal of bone and mineral research. Hoboken: Wiley, 2022, vol. 37, No 4, p. 675-686. ISSN 0884-0431. Available from: https://dx.doi.org/10.1002/jbmr.4501.

@article{1850800,
   author = {Duran, I. and Zieba, J. and Csukasi, F. and Martin, J. H. and Wachtell, D. and Barad, M. and Dawson, B. and Fafílek, Bohumil and Jacobsen, C. M. and Ambrose, C. G. and Cohn, D. H. and Krejčí, Pavel and Lee, B. H. and Krakow, D.},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1002/jbmr.4501},
   keywords = {osteogenesis imperfecta; Aga2; bone; 4-PBA; ER stress; Chop(-/ -); Bip(+/-)},
   language = {eng},
   issn = {0884-0431},
   journal = {Journal of bone and mineral research},
   title = {4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta},
   url = {https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4501},
   volume = {37},
   year = {2022}
}

TY  - JOUR
ID  - 1850800
AU  - Duran, I. - Zieba, J. - Csukasi, F. - Martin, J. H. - Wachtell, D. - Barad, M. - Dawson, B. - Fafílek, Bohumil - Jacobsen, C. M. - Ambrose, C. G. - Cohn, D. H. - Krejčí, Pavel - Lee, B. H. - Krakow, D.
PY  - 2022
TI  - 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta
JF  - Journal of bone and mineral research
VL  - 37
IS  - 4
SP  - 675-686
EP  - 675-686
PB  - Wiley
SN  - 08840431
KW  - osteogenesis imperfecta
KW  - Aga2
KW  - bone
KW  - 4-PBA
KW  - ER stress
KW  - Chop(-/ -)
KW  - Bip(+/-)
UR  - https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4501
N2  - Osteogenesis imperfecta (OI) is a genetically heterogenous disorder most often due to heterozygosity for mutations in the type I procollagen genes, COL1A1 or COL1A2. The disorder is characterized by bone fragility leading to increased fracture incidence and long-bone deformities. Although multiple mechanisms underlie OI, endoplasmic reticulum (ER) stress as a cellular response to defective collagen trafficking is emerging as a contributor to OI pathogenesis. Herein, we used 4-phenylbutiric acid (4-PBA), an established chemical chaperone, to determine if treatment of Aga2(+/-) mice, a model for moderately severe OI due to a Col1a1 structural mutation, could attenuate the phenotype. In vitro, Aga2(+/-) osteoblasts show increased protein kinase RNA-like endoplasmic reticulum kinase (PERK) activation protein levels, which improved upon treatment with 4-PBA. The in vivo data demonstrate that a postweaning 5-week 4-PBA treatment increased total body length and weight, decreased fracture incidence, increased femoral bone volume fraction (BV/TV), and increased cortical thickness. These findings were associated with in vivo evidence of decreased bone-derived protein levels of the ER stress markers binding immunoglobulin protein (BiP), CCAAT/-enhancer-binding protein homologous protein (CHOP), and activating transcription factor 4 (ATF4) as well as increased levels of the autophagosome marker light chain 3A/B (LC3A/B). Genetic ablation of CHOP in Aga2(+/-) mice resulted in increased severity of the Aga2(+/-) phenotype, suggesting that the reduction in CHOP observed in vitro after treatment is a consequence rather than a cause of reduced ER stress. These findings suggest the potential use of chemical chaperones as an adjunct treatment for forms of OI associated with ER stress. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
ER  -

DURAN, I., J. ZIEBA, F. CSUKASI, J. H. MARTIN, D. WACHTELL, M. BARAD, B. DAWSON, Bohumil FAFÍLEK, C. M. JACOBSEN, C. G. AMBROSE, D. H. COHN, Pavel KREJČÍ, B. H. LEE and D. KRAKOW. 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta. \textit{Journal of bone and mineral research}. Hoboken: Wiley, 2022, vol.~37, No~4, p.~675-686. ISSN~0884-0431. Available from: https://dx.doi.org/10.1002/jbmr.4501.

Detailed Information on Publication Record